Cardiovascular Benefits of Combination Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade in Black Hypertensive Patients.

In the ACCOMPLISH trial (Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension), combining amlodipine, rather than hydrochlorothiazide, with benazepril reduced the primary composite cardiovascular end point by 20% in hypertensive adults.1 Similar results were observed in patients with diabetes, coronary disease, chronic kidney disease, and resistant hypertension.2 As the benefits were not explained by greater blood pressure (BP)- lowering, other cardioprotective attributes of amlodipine/benazepril were likely responsible.2 We aimed to determine if this superior BP-independent cardiovascular risk reduction extends to Black participants, a key population disproportionally suffering from hypertension and the adverse health consequences. [ABSTRACT FROM AUTHOR]